LAUREN BOLLE: Open Payments
NPI 1659758688 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 40 payments from 13 companies in 2025. Trend: 2023 $889 · 2024 $869 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $199 |
| ABBVIE INC. | 8 | $164 |
| AstraZeneca Pharmaceuticals LP | 3 | $138 |
| PFIZER INC. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $52 |
| Exact Sciences Corporation | 3 | $49 |
| Abbott Laboratories | 2 | $44 |
| Lilly USA, LLC | 2 | $32 |
| Corcept Therapeutics | 1 | $31 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $28 |
Products named: Ozempic, BREZTRI, QULIPTA, UBRELVY, Veozah, Cologuard Collection Kit, Wegovy, FREESTYLE LIBRE 3.
Industry payments across GA — which companies pay providers there.
